Rani Therapeutics (NASDAQ:RANI) and Indivior (OTCMKTS:INVVY) Head to Head Survey – Defense World

Rani Therapeutics (NASDAQ:RANI Get Rating) and Indivior (OTCMKTS:INVVY Get Rating) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Rani Therapeutics and Indivior, as reported by MarketBeat.com.

Institutional & Insider Ownership

2.3% of Rani Therapeutics shares are held by institutional investors. 52.3% of Rani Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Rani Therapeutics and Indiviors net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Rani Therapeutics and Indiviors top-line revenue, earnings per share (EPS) and valuation.

Indivior has higher revenue and earnings than Rani Therapeutics. Rani Therapeutics is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Summary

Indivior beats Rani Therapeutics on 7 of the 13 factors compared between the two stocks.

Rani Therapeutics Company Profile (Get Rating)

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.

Indivior Company Profile (Get Rating)

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy products that include Temgesic, Burpex, and Buprenex. The company operates in approximately 40 countries worldwide. Indivior PLC has research collaboration agreement with Addex Therapeutics Ltd. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Receive News & Ratings for Rani Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rani Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

See the rest here:

Rani Therapeutics (NASDAQ:RANI) and Indivior (OTCMKTS:INVVY) Head to Head Survey - Defense World